Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. Show more

22722 29th Dr. SE, Bothell, WA, 98021, United States

Biotechnology

Healthcare

Market Cap

224.1M

52 Wk Range

$2.00 - $6.03

Previous Close

$4.21

Open

$4.30

Volume

803,120

Day Range

$4.06 - $4.33

Enterprise Value

201.9M

Cash

36.38M

Avg Qtr Burn

-17.98M

Insider Ownership

4.37%

Institutional Own.

46.89%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cytisinicline Details Smoking cessation	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cytisinicline Details Smoking cessation	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.